olmesartan has been researched along with diphenhydramine in 3 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (diphenhydramine) | Trials (diphenhydramine) | Recent Studies (post-2010) (diphenhydramine) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 4,146 | 415 | 542 |
| Protein | Taxonomy | olmesartan (IC50) | diphenhydramine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.98 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.542 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 1.05 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.372 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.162 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.346 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.647 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.542 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 1.295 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.98 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.171 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 1.118 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.8852 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
3 other study(ies) available for olmesartan and diphenhydramine
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |